Distinguished in Chronic Myelogenous Leukemia (CML)

Dr. Luke P. Akard

Hematology | Transplant Surgery | Oncology
Indiana Blood And Marrow Transplantation LLC
8111 S Emerson Ave, Suite 105, 
Indianapolis, IN 
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
Distinguished in Chronic Myelogenous Leukemia (CML)
Indiana Blood And Marrow Transplantation LLC
8111 S Emerson Ave, Suite 105, 
Indianapolis, IN 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Luke Akard is a Hematologist and a Transplant Surgeon in Indianapolis, Indiana. Dr. Akard is rated as a Distinguished provider by MediFind in the treatment of Chronic Myelogenous Leukemia (CML). His top areas of expertise are Acute Myeloid Leukemia (AML), Acute Myeloblastic Leukemia without Maturation, Acute Myeloblastic Leukemia with Maturation, Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Akard is currently accepting new patients.

His clinical research consists of co-authoring 28 peer reviewed articles and participating in 12 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 17 articles and participated in 3 clinical trials in the study of Chronic Myelogenous Leukemia (CML).

Specialties
Hematology
Transplant Surgery
Oncology
Licenses
Internal Medicine in IN
Hospital Affiliations
Franciscan Health Indianapolis
Languages Spoken
English
Flemish
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareSource
  • HMO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Health Alliance
  • EPO
  • HMO
  • POS
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Health Services
  • EPO
  • MANAGED MEDICAID PLAN
  • OTHER COMMERCIAL
Managed Medicaid
  • OTHER MANAGED MEDICAID
MDwise
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Meridian Choice
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 13 Less Insurance Carriers -

Locations

INDIANA BLOOD AND MARROW TRANSPLANTATION LLC
8111 S Emerson Ave, Suite 105, Indianapolis, IN 46237

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

12 Clinical Trials

Phase 1/1b, Open-label, Dose-escalation, Dose-expansion, Parallel Assignment Study to Evaluate Safety and Clinical Activity of PBCAR0191 (Azercabtagene Zapreleucel or Azer-cel) in Subjects With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)
Phase 1/1b, Open-label, Dose-escalation, Dose-expansion, Parallel Assignment Study to Evaluate Safety and Clinical Activity of PBCAR0191 (Azercabtagene Zapreleucel or Azer-cel) in Subjects With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)
Enrollment Status: Recruiting
Publish Date: March 10, 2025
Intervention Type: Drug, Biological
Study Drugs: CD19-Positive CAR-T Cells, Cyclophosphamide, Fludarabine
Study Phase: Phase 1
A Phase 3, Randomized, Open-label, Multicenter Study Comparing Ponatinib Versus Imatinib, Administered in Combination With Reduced-Intensity Chemotherapy, in Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL)
A Phase 3, Randomized, Open-label, Multicenter Study Comparing Ponatinib Versus Imatinib, Administered in Combination With Reduced-Intensity Chemotherapy, in Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL)
Enrollment Status: Active_not_recruiting
Publish Date: October 15, 2025
Intervention Type: Drug
Study Drugs: Ponatinib, Imatinib, Vincristine, Dexamethasone, Cytarabine, Methotrexate, Prednisone
Study Phase: Phase 3
A Phase 2, Open-Label, Monotherapy, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib (INCB054828) in Subjects With Myeloid/Lymphoid Neoplasms With FGFR1 Rearrangement - (FIGHT-203)
A Phase 2, Open-Label, Monotherapy, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib (INCB054828) in Subjects With Myeloid/Lymphoid Neoplasms With FGFR1 Rearrangement - (FIGHT-203)
Enrollment Status: Completed
Publish Date: July 14, 2025
Intervention Type: Drug
Study Phase: Phase 2
An Open Label, Multi-center Phase IIIb Study of Asciminib (ABL001) Monotherapy in Previously Treated Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) With and Without T315I Mutation
An Open Label, Multi-center Phase IIIb Study of Asciminib (ABL001) Monotherapy in Previously Treated Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) With and Without T315I Mutation
Enrollment Status: Completed
Publish Date: July 04, 2025
Intervention Type: Drug
Study Drug: ABL001
Study Phase: Phase 3
A Randomized, Open-label, Phase 2 Trial of Ponatinib in Patients With Resistant Chronic Phase Chronic Myeloid Leukemia to Characterize the Efficacy and Safety of a Range of Doses
A Randomized, Open-label, Phase 2 Trial of Ponatinib in Patients With Resistant Chronic Phase Chronic Myeloid Leukemia to Characterize the Efficacy and Safety of a Range of Doses
Enrollment Status: Completed
Publish Date: May 01, 2025
Intervention Type: Drug
Study Drug: Ponatinib
Study Phase: Phase 2
A Phase 3, Multi-center, Open-label, Randomized Study of Oral ABL001 Versus Bosutinib in Patients With Chronic Myelogenous Leukemia in Chronic Phase (CML-CP), Previously Treated With 2 or More Tyrosine Kinase Inhibitors
A Phase 3, Multi-center, Open-label, Randomized Study of Oral ABL001 Versus Bosutinib in Patients With Chronic Myelogenous Leukemia in Chronic Phase (CML-CP), Previously Treated With 2 or More Tyrosine Kinase Inhibitors
Enrollment Status: Completed
Publish Date: April 08, 2025
Intervention Type: Drug
Study Drugs: ABL001, Bosutinib
Study Phase: Phase 3
A Safety Trial of Lisocabtagene Maraleucel (JCAR017) for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL) in the Outpatient Setting
A Safety Trial of Lisocabtagene Maraleucel (JCAR017) for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL) in the Outpatient Setting
Enrollment Status: Completed
Publish Date: February 27, 2025
Intervention Type: Biological
Study Drug: lisocabtagene maraleucel
Study Phase: Phase 2
A Phase 3, Randomized, Double-blind, Active-Control Study of Pelabresib (CPI-0610) and Ruxolitinib vs. Placebo and Ruxolitinib in JAKi Treatment Naive MF Patients
A Phase 3, Randomized, Double-blind, Active-Control Study of Pelabresib (CPI-0610) and Ruxolitinib vs. Placebo and Ruxolitinib in JAKi Treatment Naive MF Patients
Enrollment Status: Active_not_recruiting
Publish Date: October 28, 2024
Intervention Type: Drug
Study Drugs: CPI-0610 BET Small Molecule Inhibitor, Ruxolitinib
Study Phase: Phase 3
A Phase I Study of Human Placental Hematopoietic Stem Cell Derived Natural Killer Cells (CYNK 001) in Multiple Myeloma Patients Following Autologous Stem Cell Transplant in the Front-line Setting.
A Phase I Study of Human Placental Hematopoietic Stem Cell Derived Natural Killer Cells (CYNK 001) in Multiple Myeloma Patients Following Autologous Stem Cell Transplant in the Front-line Setting.
Enrollment Status: Unknown
Publish Date: February 16, 2023
Intervention Type: Biological
Study Drug: CYNK-001
Study Phase: Phase 1
An Open-Label, Expanded Access Program of Ruxolitinib for the Treatment of Graft-Versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplant
An Open-Label, Expanded Access Program of Ruxolitinib for the Treatment of Graft-Versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplant
Enrollment Status: Approved_for_marketing
Publish Date: June 07, 2022
Intervention Type: Drug
A Phase 1 Study of ACTR087, an Autologous T Cell Product, in Combination With SEA-BCMA, a Monoclonal Antibody, in Subjects With Relapsed or Refractory Multiple Myeloma
A Phase 1 Study of ACTR087, an Autologous T Cell Product, in Combination With SEA-BCMA, a Monoclonal Antibody, in Subjects With Relapsed or Refractory Multiple Myeloma
Enrollment Status: Terminated
Publish Date: March 30, 2020
Intervention Type: Biological
Study Phase: Phase 1
An Open-Label Phase 2 Prospective, Randomized, Controlled Study of CLT-008 Myeloid Progenitor Cells as a Supportive Care Measure During Induction Chemotherapy for Acute Myeloid Leukemia
An Open-Label Phase 2 Prospective, Randomized, Controlled Study of CLT-008 Myeloid Progenitor Cells as a Supportive Care Measure During Induction Chemotherapy for Acute Myeloid Leukemia
Enrollment Status: Completed
Publish Date: September 27, 2018
Intervention Type: Biological
Study Phase: Phase 2
View 11 Less Clinical Trials

28 Total Publications

Impact of Publicly Reported Outcomes on Patient Selection for Hematopoietic Cell Transplantation.
Impact of Publicly Reported Outcomes on Patient Selection for Hematopoietic Cell Transplantation.
Journal: JCO oncology practice
Published: October 02, 2025
Similar Doctors
Distinguished in Chronic Myelogenous Leukemia (CML)
Dr. Sumeet Bhatia
Hematology | Oncology
Distinguished in Chronic Myelogenous Leukemia (CML)
Dr. Sumeet Bhatia
Hematology | Oncology

Community Physicians Of Indiana Inc

7229 Clearvista Dr, Symptom Management Group, 
Indianapolis, IN 
 (17.4 miles away)
317-621-4300
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Sumeet Bhatia is a Hematologist and an Oncologist in Indianapolis, Indiana. Dr. Bhatia is rated as a Distinguished provider by MediFind in the treatment of Chronic Myelogenous Leukemia (CML). His top areas of expertise are Small Cell Lung Cancer (SCLC), Lung Adenocarcinoma, Neuroendocrine Tumor, Bone Marrow Aspiration, and Gastrostomy.

Distinguished in Chronic Myelogenous Leukemia (CML)
Dr. Larry D. Cripe
Hematology Oncology | Hematology | Palliative Medicine
Distinguished in Chronic Myelogenous Leukemia (CML)
Dr. Larry D. Cripe
Hematology Oncology | Hematology | Palliative Medicine

Iu Health Medical Group LLC

1701 N Senate Ave, 
Indianapolis, IN 
 (10.8 miles away)
317-962-2000
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Larry Cripe is a Hematologist Oncology specialist and a Hematologist in Indianapolis, Indiana. Dr. Cripe is rated as a Distinguished provider by MediFind in the treatment of Chronic Myelogenous Leukemia (CML). His top areas of expertise are Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), Childhood Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia (CLL), and Bone Marrow Aspiration. Dr. Cripe is currently accepting new patients.

Advanced in Chronic Myelogenous Leukemia (CML)
Dr. Seyed H. Sayar
Hematology Oncology | Oncology | Hematology
Advanced in Chronic Myelogenous Leukemia (CML)
Dr. Seyed H. Sayar
Hematology Oncology | Oncology | Hematology

Indiana University Health Care Associates Inc

535 Barnhill Dr, 
Indianapolis, IN 
 (10.2 miles away)
317-944-4897
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Seyed Sayar is a Hematologist Oncology specialist and an Oncologist in Indianapolis, Indiana. Dr. Sayar is rated as a Distinguished provider by MediFind in the treatment of Chronic Myelogenous Leukemia (CML). His top areas of expertise are Acute Myeloblastic Leukemia without Maturation, Acute Myeloid Leukemia (AML), Multiple Myeloma, Myelodysplastic Syndrome (MDS), and Bone Marrow Aspiration. Dr. Sayar is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Akard's expertise for a condition
ConditionClose
    View All 7 Distinguished Conditions
    View All 11 Advanced Conditions
    View All 29 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile